251 related articles for article (PubMed ID: 20361185)
1. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.
Gabitzsch ES; Xu Y; Balint JP; Hartman ZC; Lyerly HK; Jones FR
Cancer Immunol Immunother; 2010 Jul; 59(7):1131-5. PubMed ID: 20361185
[TBL] [Abstract][Full Text] [Related]
2. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
[TBL] [Abstract][Full Text] [Related]
3. Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients.
Morse MA; Chaudhry A; Gabitzsch ES; Hobeika AC; Osada T; Clay TM; Amalfitano A; Burnett BK; Devi GR; Hsu DS; Xu Y; Balcaitis S; Dua R; Nguyen S; Balint JP; Jones FR; Lyerly HK
Cancer Immunol Immunother; 2013 Aug; 62(8):1293-301. PubMed ID: 23624851
[TBL] [Abstract][Full Text] [Related]
4. Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
Osada T; Yang XY; Hartman ZC; Glass O; Hodges BL; Niedzwiecki D; Morse MA; Lyerly HK; Amalfitano A; Clay TM
Cancer Gene Ther; 2009 Sep; 16(9):673-82. PubMed ID: 19229288
[TBL] [Abstract][Full Text] [Related]
5. A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant-based vaccine used to induce cell mediated immune responses.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Gayle RB; Amalfitano A; Jones FR
Immunol Lett; 2009 Jan; 122(1):44-51. PubMed ID: 19073216
[TBL] [Abstract][Full Text] [Related]
6. An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.
Gabitzsch ES; Xu Y; Balcaitis S; Balint JP; Jones FR
Cancer Gene Ther; 2011 May; 18(5):326-35. PubMed ID: 21233857
[TBL] [Abstract][Full Text] [Related]
7. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity.
Roberts DM; Nanda A; Havenga MJ; Abbink P; Lynch DM; Ewald BA; Liu J; Thorner AR; Swanson PE; Gorgone DA; Lifton MA; Lemckert AA; Holterman L; Chen B; Dilraj A; Carville A; Mansfield KG; Goudsmit J; Barouch DH
Nature; 2006 May; 441(7090):239-43. PubMed ID: 16625206
[TBL] [Abstract][Full Text] [Related]
8. Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.
Gabitzsch ES; Balint-Junior JP; Xu Y; Balcaitis S; Sanders-Beer B; Karl J; Weinhold KJ; Paessler S; Jones FR
Vaccine; 2012 Nov; 30(50):7265-70. PubMed ID: 23041546
[TBL] [Abstract][Full Text] [Related]
9. Vaccine therapy of established tumors in the absence of autoimmunity.
Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
[TBL] [Abstract][Full Text] [Related]
10. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
11. Induction and comparison of SIV immunity in Ad5 naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine.
Gabitzsch ES; Xu Y; Balint JP; Balcaitis S; Sanders-Beer B; Jones FR
Vaccine; 2011 Oct; 29(45):8101-7. PubMed ID: 21864618
[TBL] [Abstract][Full Text] [Related]
12. Efficient co-transduction of adenoviral vectors encoding carcinoembryonic antigen and survivin into dendritic cells by the CAR-TAT adaptor molecule enhance anti-tumor immunity in a murine colorectal cancer model.
Kim HS; Kim CH; Park MY; Park JS; Park HM; Sohn HJ; Kim HJ; Kim SG; Oh ST; Kim TG
Immunol Lett; 2010 Jun; 131(1):73-80. PubMed ID: 20211203
[TBL] [Abstract][Full Text] [Related]
13. Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.
Balint JP; Gabitzsch ES; Rice A; Latchman Y; Xu Y; Messerschmidt GL; Chaudhry A; Morse MA; Jones FR
Cancer Immunol Immunother; 2015 Aug; 64(8):977-87. PubMed ID: 25956394
[TBL] [Abstract][Full Text] [Related]
14. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.
Gabitzsch ES; Xu Y; Yoshida LH; Balint J; Amalfitano A; Jones FR
Vaccine; 2009 Oct; 27(46):6394-8. PubMed ID: 19559110
[TBL] [Abstract][Full Text] [Related]
15. An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.
Ophorst OJ; Kostense S; Goudsmit J; De Swart RL; Verhaagh S; Zakhartchouk A; Van Meijer M; Sprangers M; Van Amerongen G; Yüksel S; Osterhaus AD; Havenga MJ
Vaccine; 2004 Aug; 22(23-24):3035-44. PubMed ID: 15297053
[TBL] [Abstract][Full Text] [Related]
16. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen.
Baral RN; Saha A; Chatterjee S; Foon KA; Krieg A; Weiner GJ; Bhattacharya-Chatterjee M
Cancer Immunol Immunother; 2003 May; 52(5):317-27. PubMed ID: 12700947
[TBL] [Abstract][Full Text] [Related]
18. A Cre-expressing cell line and an E1/E2a double-deleted virus for preparation of helper-dependent adenovirus vector.
Zhou H; Zhao T; Pastore L; Nageh M; Zheng W; Rao XM; Beaudet AL
Mol Ther; 2001 Apr; 3(4):613-22. PubMed ID: 11319924
[TBL] [Abstract][Full Text] [Related]
19. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
20. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
Xin KQ; Jounai N; Someya K; Honma K; Mizuguchi H; Naganawa S; Kitamura K; Hayakawa T; Saha S; Takeshita F; Okuda K; Honda M; Klinman DM; Okuda K
Gene Ther; 2005 Dec; 12(24):1769-77. PubMed ID: 16079886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]